Laboratoire d'Hématologie Cellulaire, Centre Hospitalier Lyon-Sud, Pierre-Bénite, France.
Mod Pathol. 2011 Jul;24(7):993-1003. doi: 10.1038/modpathol.2011.53. Epub 2011 Apr 15.
Angioimmunoblastic T-cell lymphoma is immunologically defined by the expression of CD10 and the follicular helper T cell (T(FH)) markers such as CXCL13, programmed death-1 (PD-1) and inducible T-cell costimulator (ICOS). This T(FH) profile has been mainly reported by immunohistochemistry. Here, using multiparametric flow cytometry, the relevance of ICOS and PD-1 to angioimmunoblastic T-cell lymphoma diagnosis was evaluated in lymph node (n=15) as well as in peripheral blood (n=13) among a series of 28 angioimmunoblastic T-cell lymphoma cases, in addition to the CD10 expression (available in 26 lymph node and 15 peripheral blood specimens). In this series, CD10 expression was present in 23/26 (88%) lymph node and in 12/15 (80%) peripheral blood cases and ICOS in 13/15 (87%) lymph node and in 6/13 (47%) peripheral blood cases, whereas neither significant CD10 nor ICOS T cells were identified in the control group (lymph nodes with reactive hyperplasia=10, peripheral blood of healthy donors=15). PD-1 expression was less informative as observed in both angioimmunoblastic T-cell lymphoma and control cases. The multiparametric approach allowed us to confirm the frequent blood dissemination in angioimmunoblastic T-cell lymphoma and to show that circulating neoplastic T cells correspond more often to a CD10-positive subset than to an ICOS-positive subset. Consequently, if ICOS constitutes an additional feature for the diagnosis of angioimmunoblastic T-cell lymphoma, it appears less sensitive than CD10 expression for the detection of circulating neoplastic T cells.
血管免疫母细胞性 T 细胞淋巴瘤在免疫学上通过表达 CD10 和滤泡辅助 T 细胞(T(FH))标志物(如 CXCL13、程序性死亡受体 1(PD-1)和诱导性 T 细胞共刺激因子(ICOS))来定义。这种 T(FH)表型主要通过免疫组织化学报告。在这里,通过多参数流式细胞术,在 28 例血管免疫母细胞性 T 细胞淋巴瘤病例中,除了 CD10 表达(在 26 个淋巴结和 15 个外周血标本中可用)外,评估了 ICOS 和 PD-1 在淋巴结(n=15)和外周血(n=13)中的相关性,用于血管免疫母细胞性 T 细胞淋巴瘤的诊断。在这个系列中,CD10 表达存在于 23/26(88%)淋巴结和 12/15(80%)外周血病例中,ICOS 存在于 13/15(87%)淋巴结和 6/13(47%)外周血病例中,而在对照组(反应性增生性淋巴结=10,健康供体的外周血=15)中均未发现明显的 CD10 或 ICOS T 细胞。PD-1 表达在血管免疫母细胞性 T 细胞淋巴瘤和对照病例中均不具有信息性。多参数方法使我们能够确认血管免疫母细胞性 T 细胞淋巴瘤中频繁的血液传播,并表明循环肿瘤 T 细胞更常对应于 CD10 阳性亚群,而不是 ICOS 阳性亚群。因此,如果 ICOS 构成血管免疫母细胞性 T 细胞淋巴瘤诊断的附加特征,其对循环肿瘤 T 细胞的检测敏感性似乎低于 CD10 表达。